

Contents

	<i>Page</i>
Introduction	3
History of the Artificial Heart.	4
Pool of Potential Recipients in the United States.	5
Sources of Candidates.	5
Estimates of Potential Candidates in the United States, 1979.	6
Patient Access to Implant Hospitals and Patient Refusal	8
Economic Aspects	8
Artificial Cardiac Pacemaker.	8
Coronary Artery Bypass Grafts.	9
Heart Transplants	9
Device Costs	10
Summary of Costs	11
Personnel and Facilities.	12
R&D Funding	13
Parallel Costs of Hemodialysis	16
Estimates of the Potential Success of the Artificial Heart	18
LVAD Research and Clinical Trials.	18
Instrument Reliability	20
Quality of Life Parameters.	21
Hemodialysis and Kidney Transplants.	21
Cardiac Transplants.	22
Problems of a Nuclear-Powered Heart	22
Discussion	23
Social Benefits.	24
Extension of Life.	24
Return to Work.	28
Social Costs	29
Increased Social Expenditures.	29
Distributional Issues.	31
Social Costs of a Nuclear Device.	31
Opportunity Costs.	31
Cardiac Disease Prevention	32
Policy Recommendations.	35
Program Administration	35
Regulation	36
Reimbursement and Distribution	37
Summary	38
Appendix A: The Artificial Cardiac Pacemaker.	41
Appendix B: Cardiac Transplant Costs	44
Appendix C: NHLBI R&D Contracts and Grants.	45
Appendix D: Stanford Heart Disease Prevention Program Materials	90
References	92

LIST OF TABLES

<i>Table No.</i>	<i>Page</i>
1. Three Estimates of Major Items of Expense Associated With Artificial Heart Implantation and Use.	11
2. Effect of Numbers of Implants unavailable Societal Resources	12

<i>Table No.</i>	<i>Page</i>
3. NHLBI Devices and Technology Branch Contract Funding, Fiscal Year; 1964-79.	14
4. Financial History of the Artificial Heart Program at the Department of Energy,	15
5. Estimated Annual Costs for the ESRD Program	17
6. Fraction of Those With IHD in Each Age Interval That Gets the Device—Best and Worst Case.	25
7. Proportion of Those Obtaining the Device That Dies Due to Device Failure at Subsequent Ages—Best Case.	26
8. Proportion of Those Obtaining the Device That Dies Due to Device Failure at Subsequent Ages—Worst Case.	26
9. Age-Specific Death Rates Due to All Causes, 1977.	26
10. Age-Specific Death Rates Due to IHD, 1977.	26
11. Increase in Life Expectancy in Years for Randomly Selected Individuals of Specified Ages Who May or May Not Develop IHD—Best and Worst Case.	27
12. Increase in Life Expectancy in Years for Individuals of Specified Ages Who Will Ultimately Develop IHD—Best and Worst Case.	27
13. Projected S-Year Sequence of Total National Expenditures on Artificial Heart Implantation and Patient Maintenance.	30
14. SHDPP Expenses by Media Campaign.	34
A-1. Pacemaker Longevity Excluding Causes of Failure Other Than Battery Exhaustion.	41
B-1. Cardiac Transplant Hospitalization Costs, 1969-75	44
B-2. Cardiac Transplant Outpatient Costs, 1969-75	44
D-1. SHDPP Three-Community Study Design.	90
D-2. Demographic Characteristics and Survey Response Rates in Each of the Three Communities	90
D-3. Risk Indicator and Knowledge Sources: Percentage Change From Baseline at 1, 2, and 3 Follow up Surveys.	91
D-4. SHDPP Expenses By Media Campaign	91

LIST OF FIGURES

<i>Figure No.</i>	<i>Page</i>
1. Comparative Program Growth: NIH, NHLBI, and the Artificial Heart Program, Fiscal Years 1964-75.	14
2. Percentage Change in Risk of CHD After 1 and 2 Years of Health Education in Various Study Groups From Three Communities.	33